Etifoxine (and therefore GRX-917) has an excellent safety/pharmacological profile, based on a safety profile review by ANSM in France (2000-2012) which analyzed over 14 million prescriptions of etifoxine.

  • Non addictive (no cases of abuse, misuse or pharmacodependence)
  • No tolerance, withdrawal or rebound
  • Low ADRs (21 per million) based on +14 million prescriptions analyzed in France (2000-2012)
  • SAEs are very rare and occur less frequently than with both first line and second-line anxiolytics